销售-话题@MedSci

#销售#

155篇内容 | 1433人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1687397, encodeId=456a168e3972a, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=国家药监局拟规定：第三方平台不能直接网络销售药品, objectType=article, longId=730564, objectId=4583e3056449, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4583e3056449, replyNumber=0, likeNumber=40, createdTime=2022-07-26, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4583e3056449, moduleTitle=国家药监局拟规定：第三方平台不能直接网络销售药品, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4583e3056449)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687394, encodeId=662a168e3944b, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=赛诺菲度普利尤单抗治疗儿童湿疹适应症国内NMPA获准；全球销售达60亿美元, objectType=article, longId=300219, objectId=bbdd30021914, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbdd30021914, replyNumber=0, likeNumber=53, createdTime=2022-11-16, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbdd30021914, moduleTitle=赛诺菲度普利尤单抗治疗儿童湿疹适应症国内NMPA获准；全球销售达60亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbdd30021914)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687393, encodeId=e7fe168e39327, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=处方药可以在互联网上销售了？, objectType=article, longId=294815, objectId=02ff29481596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02ff29481596, replyNumber=0, likeNumber=32, createdTime=2022-07-06, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02ff29481596, moduleTitle=处方药可以在互联网上销售了？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02ff29481596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687396, encodeId=7118168e396c3, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售, objectType=article, longId=300761, objectId=3b82300e6134, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b82300e6134, replyNumber=0, likeNumber=56, createdTime=2022-04-02, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b82300e6134, moduleTitle=Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b82300e6134)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687395, encodeId=0a44168e3957e, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=2022年3月10日简报：本土感染连续3天超500例，无头疫情增多；香港新增25991例确诊病例，疫情好转；中国医药确认拿下2022年度辉瑞新冠特效药在大陆的销售权, objectType=article, longId=300415, objectId=3d5e3004157b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d5e3004157b, replyNumber=0, likeNumber=34, createdTime=2022-10-28, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d5e3004157b, moduleTitle=2022年3月10日简报：本土感染连续3天超500例，无头疫情增多；香港新增25991例确诊病例，疫情好转；中国医药确认拿下2022年度辉瑞新冠特效药在大陆的销售权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d5e3004157b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687392, encodeId=8861168e39253, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=欧洲药品管理局接受Enfortumab Vedotin的销售授权申请（MAA）, objectType=article, longId=209110, objectId=46be20911056, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46be20911056, replyNumber=0, likeNumber=53, createdTime=2021-07-21, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46be20911056, moduleTitle=欧洲药品管理局接受Enfortumab Vedotin的销售授权申请（MAA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46be20911056)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687388, encodeId=4285168e388a7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=病毒RNA聚合酶抑制剂AT-527治疗COVID-19，Chugai制药公司将负责日本的开发和销售, objectType=article, longId=207374, objectId=789020e3747d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=789020e3747d, replyNumber=0, likeNumber=44, createdTime=2021-08-01, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=789020e3747d, moduleTitle=病毒RNA聚合酶抑制剂AT-527治疗COVID-19，Chugai制药公司将负责日本的开发和销售, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=789020e3747d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687387, encodeId=faf1168e387b9, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=用生理盐水假冒新冠疫苗销售！80多人被抓, objectType=article, longId=206627, objectId=8a7f20662ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a7f20662ed0, replyNumber=0, likeNumber=44, createdTime=2021-07-27, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a7f20662ed0, moduleTitle=用生理盐水假冒新冠疫苗销售！80多人被抓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a7f20662ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687391, encodeId=976b168e39142, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）, objectType=article, longId=209073, objectId=c97e2090e362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c97e2090e362, replyNumber=0, likeNumber=49, createdTime=2021-06-05, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c97e2090e362, moduleTitle=EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c97e2090e362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687389, encodeId=eaa7168e389fc, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=连花清瘟2020年销售额或已达40亿, objectType=article, longId=208093, objectId=ad88208093ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad88208093ef, replyNumber=0, likeNumber=40, createdTime=2021-06-01, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad88208093ef, moduleTitle=连花清瘟2020年销售额或已达40亿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad88208093ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687384, encodeId=36ef168e384fc, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=分析师预测：新冠疫苗2021年销售额可达380亿美元, objectType=article, longId=204183, objectId=4d6720418352, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d6720418352, replyNumber=0, likeNumber=39, createdTime=2020-12-24, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d6720418352, moduleTitle=分析师预测：新冠疫苗2021年销售额可达380亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d6720418352)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687380, encodeId=1a28168e38095, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=吉利德收回瑞德西韦供应控制权，预计今年销售收入将达35亿美元, objectType=article, longId=201691, objectId=6992201691fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6992201691fa, replyNumber=0, likeNumber=47, createdTime=2021-08-03, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6992201691fa, moduleTitle=吉利德收回瑞德西韦供应控制权，预计今年销售收入将达35亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6992201691fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687386, encodeId=86e1168e3864b, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=山东涉疫奶枣已销售22吨，涉及北京、上海等26个省份, objectType=article, longId=206597, objectId=14cc20659e27, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14cc20659e27, replyNumber=0, likeNumber=34, createdTime=2021-08-16, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14cc20659e27, moduleTitle=山东涉疫奶枣已销售22吨，涉及北京、上海等26个省份, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14cc20659e27)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687390, encodeId=9b95168e39043, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=拜耳去年净亏损约105亿欧元，销售榜首利伐沙班面临专利悬崖, objectType=article, longId=208154, objectId=66cc208154dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66cc208154dd, replyNumber=0, likeNumber=41, createdTime=2021-08-28, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66cc208154dd, moduleTitle=拜耳去年净亏损约105亿欧元，销售榜首利伐沙班面临专利悬崖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66cc208154dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687374, encodeId=596f168e3741d, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=306家药企销售费用共花2793亿！8家制药企业超50亿，医疗企业平均花3亿, objectType=article, longId=193535, objectId=199d193535dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=199d193535dc, replyNumber=0, likeNumber=31, createdTime=2020-12-17, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=199d193535dc, moduleTitle=306家药企销售费用共花2793亿！8家制药企业超50亿，医疗企业平均花3亿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=199d193535dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687381, encodeId=bb96168e381a0, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=瑞德西韦第三季度销售超8亿美元, objectType=article, longId=202827, objectId=d50020282e05, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d50020282e05, replyNumber=0, likeNumber=30, createdTime=2020-12-21, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d50020282e05, moduleTitle=瑞德西韦第三季度销售超8亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d50020282e05)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687385, encodeId=9eb6168e385b4, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=黑龙江黑河市：禁止网络销售、购买“退烧止咳抗病毒”药品, objectType=article, longId=205567, objectId=51b320556e4f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51b320556e4f, replyNumber=0, likeNumber=53, createdTime=2021-10-14, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51b320556e4f, moduleTitle=黑龙江黑河市：禁止网络销售、购买“退烧止咳抗病毒”药品, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51b320556e4f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687383, encodeId=1d06168e38379, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=从8款PD-1/PD-L1前三季度销售收入猜想医保谈判, objectType=article, longId=204144, objectId=72f620414451, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72f620414451, replyNumber=0, likeNumber=27, createdTime=2021-08-03, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72f620414451, moduleTitle=从8款PD-1/PD-L1前三季度销售收入猜想医保谈判, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72f620414451)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687372, encodeId=1883168e3722b, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=EMA接受抗部分性癫痫发作药物cenobamate的销售授权申请, objectType=article, longId=191490, objectId=c3f6191490db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3f6191490db, replyNumber=0, likeNumber=38, createdTime=2020-11-03, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3f6191490db, moduleTitle=EMA接受抗部分性癫痫发作药物cenobamate的销售授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3f6191490db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1687373, encodeId=6260168e37345, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, objectTitle=2019年全球药品销售额TOP100，肿瘤与自身免疫蛋糕惊人, objectType=article, longId=192261, objectId=a26d192261dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a26d192261dd, replyNumber=0, likeNumber=49, createdTime=2020-12-12, rootId=0, userName=1249862am81(暂无昵称), userId=0bca28361924, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a26d192261dd, moduleTitle=2019年全球药品销售额TOP100，肿瘤与自身免疫蛋糕惊人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a26d192261dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

国家药监局拟规定：第三方平台不能直接网络销售药品

2022-07-26

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

赛诺菲度普利尤单抗治疗儿童湿疹适应症国内NMPA获准；全球销售达60亿美元

2022-11-16

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

处方药可以在互联网上销售了？

2022-07-06

智者为医08 (审核中...)

前往app查看评论内容

#销售#

Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售

2022-04-02

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

2022年3月10日简报：本土感染连续3天超500例，无头疫情增多；香港新增25991例确诊病例，疫情好转；中国医药确认拿下2022年度辉瑞新冠特效药在大陆的销售权

2022-10-28

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

欧洲药品管理局接受Enfortumab Vedotin的销售授权申请（MAA）

2021-07-21

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

病毒RNA聚合酶抑制剂AT-527治疗COVID-19，Chugai制药公司将负责日本的开发和销售

2021-08-01

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

用生理盐水假冒新冠疫苗销售！80多人被抓

2021-07-27

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）

2021-06-05

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

连花清瘟2020年销售额或已达40亿

2021-06-01

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

分析师预测：新冠疫苗2021年销售额可达380亿美元

2020-12-24

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

吉利德收回瑞德西韦供应控制权，预计今年销售收入将达35亿美元

2021-08-03

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

山东涉疫奶枣已销售22吨，涉及北京、上海等26个省份

2021-08-16

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

拜耳去年净亏损约105亿欧元，销售榜首利伐沙班面临专利悬崖

2021-08-28

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

306家药企销售费用共花2793亿！8家制药企业超50亿，医疗企业平均花3亿

2020-12-17

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

瑞德西韦第三季度销售超8亿美元

2020-12-21

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

黑龙江黑河市：禁止网络销售、购买“退烧止咳抗病毒”药品

2021-10-14

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

从8款PD-1/PD-L1前三季度销售收入猜想医保谈判

2021-08-03

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

EMA接受抗部分性癫痫发作药物cenobamate的销售授权申请

2020-11-03

1249862am81(暂无昵称) (审核中...)

前往app查看评论内容

#销售#

2019年全球药品销售额TOP100，肿瘤与自身免疫蛋糕惊人

2020-12-12

科室
- - 订阅+
  - 更多科室
工具
服务